Weight Loss Velocity and Patulous Eustachian Tube Chronicity After Bariatric Surgery.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42627248.
- Also identified by DOI 10.1002/lary.70858.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the relationship between weight loss velocity following bariatric surgery and the onset and long-term persistence of Patulous Eustachian Tube (PET) symptoms. Sixty patients who underwent laparoscopic sleeve gastrectomy were prospectively evaluated. Otological assessments and the Eustachian Tube Dysfunction Questionnaire (ETDQ-7) were completed preoperatively and postoperatively at 1, 3, 6, and 12 months. Patients were categorized into Asymptomatic (Group 1), Recovered (Group 2), and Persistent (Group 3) groups based on 12-month clinical trajectories. Postoperative weight loss velocity was calculated via periodic BMI (Body Mass Index) change rates (ΔBMI%). The overall PET symptom onset rate was 55.0% (n = 33), with 43.3% (n = 26) experiencing spontaneous resolution and 11.7% (n = 7) developing chronic symptoms. No significant difference was found in 12-month excess weight loss percentage (%EWL) success rates among groups (p = 0.577). However, BMI decline velocities demonstrated highly significant intergroup variances (p < 0.001). ROC analysis revealed that an initial 0-3 month BMI decline exceeding 25.0% significantly predicted symptom onset (p = 0.003). Remarkably, a 3-6 month BMI decline velocity above 22.4% predicted long-term symptom chronicity. (p < 0.001), yielding a sensitivity and negative predictive value of 100%. Higher preoperative BMI was significantly associated with symptom persistence. The onset and long-term persistence of post-bariatric PET symptoms are fundamentally dictated by postoperative weight loss velocity rather than absolute weight loss. A sustained high-velocity BMI decline between Months 3 and 6 serves as the definitive clinical predictor for chronicity, demanding close monitoring.